title: Control of inflammation and prophylaxis of endophthalmitis after cataract surgery: a multicenter study.
abstract: OBJECTIVE
  To compare two different postcataract surgery antibiotic/steroid therapeutic combinations, for clinical results as well as patient satisfaction.
  
  
  METHODS
  Prospective randomized clinical trial of patients with bilateral operative cataract. Postoperatively, for 15 days one eye was randomly assigned to therapy with the combination chloramphenicol 0.25%-betamethasone 0.13% gel three times a day (Group 1) and the other to the combination tobramycin 0.3%-dexamethasone 0.1% eyedrops four times a day (Group 2).
  
  
  RESULTS
  A total of 142 patients (284 eyes) completed the study. The authors could not detect any significant difference between Group 1 and Group 2 concerning preoperative evaluation, surgical procedure, and complications. Pertaining to the two therapeutic regimens, efficacy, side effects, and clinical findings such as uncorrected visual acuity, intraocular pressure, edema or hyperemia of eyelids and/or conjunctiva, conjunctival and/or ciliary vessels congestion, decreased corneal transparency, corneal edema, Descemet folds, anterior chamber Tyndall and depth, and posterior synechiae were also comparable. Postoperative subjective pain and dry eye sensation were comparable between the two groups, while the gel preparation elicited a significantly more pleasant sensation in the patients (p=0.04).
  
  
  CONCLUSIONS
  The motivation for use of a gel is to prolong the permanence of associated drugs on the ocular surface, increasing potency and decreasing concentration of the drug and rate of administration. This in order to improve compliance and decrease potential side effects. Chloramphenicol 0.25%-betamethasone 0.13% gel combination proved to have comparable efficacy, tolerance, and better acceptance by the patients than an aqueous tobramycin 0.3%-dexamethasone 0.1% preparation.
authors.affiliation: Department of Ophthalmology, Istituto Clinico Humanitas, Rozzano, Milano, Italy. fabrizio.camesasca@tiscali.it
authors.forename: F I
authors.initials: FI
authors.lastname: Camesasca
authors.forename: C
authors.initials: C
authors.lastname: Bianchi
authors.forename: G
authors.initials: G
authors.lastname: Beltrame
authors.forename: A
authors.initials: A
authors.lastname: Caporossi
authors.forename: M
authors.initials: M
authors.lastname: Piovella
authors.forename: A
authors.initials: A
authors.lastname: Rapisarda
authors.forename: G
authors.initials: G
authors.lastname: Tassinari
authors.forename: L
authors.initials: L
authors.lastname: Zeppa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001623:Betamethasone / Q000008:administration & dosage*; D002387:Cataract Extraction / Q000009:adverse effects*; D002701:Chloramphenicol / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D005782:Gels; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011183:Postoperative Complications; D011446:Prospective Studies; D014031:Tobramycin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005782:Gels; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D002701:Chloramphenicol; D003907:Dexamethasone; D001623:Betamethasone; D014031:Tobramycin